Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenstrom's Macroglobulinemia

Trial Profile

Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenstrom's Macroglobulinemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Rituximab
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Oct 2016 This trial was suspended in Greece, according to European Clinical Trials Database.
    • 20 Oct 2016 This trial was suspended in Portugal, according to European Clinical Trials Database.
    • 10 Sep 2015 Final Results published in the Blood (letter).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top